Generated by AI
Incyte Corp. is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The company’s current portfolio centers on hematology, oncology, and inflammation and autoimmunity, with products and programs aimed at treating cancers, blood disorders, and immune-mediated conditions. Incyte Corp. develops both small-molecule medicines and biologics, and its marketed therapies support patients with a range of specialty disease areas, including dermatology and rare hematologic disorders. The company also maintains a pipeline of clinical-stage candidates across its core therapeutic franchises, reflecting its role as a research-driven developer of targeted treatments. Headquartered in Wilmington, Delaware, Incyte Corp. serves healthcare markets in the United States and internationally through its commercial and development activities.
Website1801 Augustine Cut-Off
Wilmington, DE, 19803
United States
The latest articles about INCY.
Summary of Oct 29's posts. Generated by AI.
Summary of Jan 10's posts. Generated by AI.
Summary of Jun 8's posts. Generated by AI.
Summary of Oct 29's posts. Generated by AI.
Investors talking about INCY also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.